Table 2.
Best radiological responses.
| All (N = 33) |
SOR/NIVO (N = 8) |
SOR/PEMBRO (N = 4) |
LEN/NIVO (N = 11) |
LEN/PEMBRO (N = 10) |
p-Value | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | N | % | N | % | |||
| mRECIST | 0.279 | |||||||||||
| CR | 2 | (6.1%) | 0 | 1 | (25.0%) | 1 | (7.4%) | 0 | ||||
| PR | 14 | (42.4%) | 2 | (25.0%) | 2 | (50.0%) | 3 | (44.4%) | 7 | (70.0%) | ||
| SD | 8 | (24.2%) | 2 | (25.0%) | 1 | (25.0%) | 4 | (22.3%) | 1 | (10.0%) | ||
| PD | 9 | (27.3%) | 4 | (50.0%) | 0 | 3 | (25.9%) | 2 | (20.0%) | |||
| ORR | 16 | (48.5%) | 2 | (25.0%) | 3 | (75.0%) | 4 | (51.8%) | 7 | (70.0%) | 0.145 | |
| DCR | 24 | (72.7%) | 4 | (50.0%) | 4 | (100%) | 8 | (74.1%) | 8 | (80.0%) | 0.278 | |
All p-values were analyzed with Pearson’s Chi-square test. Abbreviations: CR, complete response; DCR, disease control rate; LEN, lenvatinib; N, number of patients; NIVO, nivolumab; ORR, objective response rate; PD, progressive disease; PEMBRO, pembrolizumab; PR, partial response; SD, stable disease; SOR, sorafenib.